CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...